Crowdfund 2014 AA treatment pipeline report

[sosa56]

Hello,

I think we should club together $2000 and get this report - http://www.aboutpharma.com/blog/2014...search-report/

It provides info on all of the treatments in the works, some I've never heard of before along with info on their state of development and mechanisms of action, I reckon it could give everyone a good overview of the state of affairs where we're at etc. before the conference in Nov and perhaps spur further research etc.

I'd happily chip in $20, preferably a trusted/reputable forum member could coordinate the sourcing of funds and purchasing/uploading of report.

[NeedHairASAP]

Hello,

I think we should club together $2000 and get this report - http://www.aboutpharma.com/blog/2014...search-report/

It provides info on all of the treatments in the works, some I've never heard of before along with info on their state of development and mechanisms of action, I reckon it could give everyone a good overview of the state of affairs where we're at etc. before the conference in Nov and perhaps spur further research etc.

I'd happily chip in $20, preferably a trusted/reputable forum member could coordinate the sourcing of funds and purchasing/uploading of report.

Probably not much extra info in there.... just google the companies you haven't heard of

[NeedHairASAP]

Drugs profile discussed in this Pompe disease Pipeline Review H2 2014 report include

bimatoprost, meh.


CB-0301, meh.


finasteride, ....


Hair Stimulating Complex, meh.



RCH-01, replicel



Refagro,

http://www.reportlinker.com/p01667369-summary/Kasiak-Research-Pvt-Ltd-Product-Pipeline-Review.html

RES-440,

RES-440, an ester of a carboxylic acid derivative of hydroxyflutamide, is a synthetic, non-steroidal compound and represents one of four structural classes of topical anti-androgenic compounds in the RestorGenex portfolio. Management believes RES-440 is the first topical anti-androgen engineered for rapid deactivation by hydrolytic enzymes near the site of application to a single inactive metabolite, thus, sparing internal androgen sensitive tissues. Our data demonstrate that RES-440 is a very potent anti-androgen. RES-441, the expected major metabolite of RES-440 has no detectable anti-androgenic activity. To date, no other topical anti-androgen has been developed and marketed successfully. We believe the root cause of this failure has been due to the systemic safety issues that arise with locally effective doses.

RES-440 is currently under development for the treatment of acne.

Excess androgenic hormones (testosterone and 5-dihydrotestosterone) in the skin are the root cause of acne, seborrhea, alopecia and hirsutism. Excess skin androgens lead to the overproduction of sebum which can block skin pores and lead to acne through localized infection and inflammation. A topical anti-androgen may block the actions of androgenic hormones in the skin and heal acne. In some women, excess skin androgens can lead to unwanted localized hair growth (hirsutism). A topical anti-androgen applied to those skin areas may greatly minimize excess body hair growth caused by excess androgens in the skin. Paradoxically, excess androgen in the scalp can cause androgenic alopecia or baldness and is the most common cause of hair loss affecting both men and women. An anti-androgen applied to the scalp at the first signs of thinning may block the actions of androgenic hormones.


RK-023,

In January 2011, the company announced that the Phase 2a clinical study of RK-023 to treat androgenetic alopecia has been completed. The double-blind, placebo-controlled study assessed the safety and preliminary efficacy of RK-023 when applied to the scalp for 13 weeks (2 mL to a hair-thinning part of scalp twice daily). Forty-eight patients (24 cases of the RK-023 group and 24 cases of the placebo group) were enrolled in this study. There was no severe adverse event. The frequency of mild adverse events was equal in both groups. In pharmacokinetic study, the main metabolite of RK-023 was slightly detected in plasma of only one patient. This showed that the transdermal absorption of RK-023 from the scalp was low. In the efficacy assessment, the RK-023 group showed possibility of improvement in global photo assessment and in numbers of anagen hair from the baseline compared with the placebo group.


SM-04554, meh. Doubt more info here then we know.


Small Molecule for Androgenic Alopecia, vague



pay me $2,000 now

[NeedHairASAP]

ntents: List of Tables
List of Figures
Introduction
REPORT COVERAGE
Androgenic Alopecia Overview
Therapeutics Development
Pipeline Products for Androgenic Alopecia - Overview
Pipeline Products for Androgenic Alopecia - Comparative Analysis
Androgenic Alopecia - Therapeutics under Development by Companies
Androgenic Alopecia - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Androgenic Alopecia - Products under Development by Companies
Androgenic Alopecia - Companies Involved in Therapeutics Development
Allergan, Inc.
Dong-A Socio Group
Histogen, Inc.
Kasiak Research Pvt. Ltd.
Molplex Ltd.
Polichem S.A.
R-Tech Ueno, Ltd.
RepliCel Life Sciences, Inc.
RestorGenex Corporation
SWITCH Biotech LLC
Valeant Pharmaceuticals International, Inc.
Androgenic Alopecia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(finasteride + minoxidil) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bimatoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-0301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
finasteride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hair Stimulating Complex (HSC) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RCH-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Refagro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RES-440 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RK-023 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SM-04554 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Androgenic Alopecia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Androgenic Alopecia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Androgenic Alopecia - Recent Pipeline Updates
Androgenic Alopecia - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Androgenic Alopecia, H2 2014
Number of Products under Development for Androgenic Alopecia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Androgenic Alopecia - Pipeline by Allergan, Inc., H2 2014
Androgenic Alopecia - Pipeline by Dong-A Socio Group, H2 2014
Androgenic Alopecia - Pipeline by Histogen, Inc., H2 2014
Androgenic Alopecia - Pipeline by Kasiak Research Pvt. Ltd., H2 2014
Androgenic Alopecia - Pipeline by Molplex Ltd., H2 2014
Androgenic Alopecia - Pipeline by Polichem S.A., H2 2014
Androgenic Alopecia - Pipeline by R-Tech Ueno, Ltd., H2 2014
Androgenic Alopecia - Pipeline by RepliCel Life Sciences, Inc., H2 2014
Androgenic Alopecia - Pipeline by RestorGenex Corporation, H2 2014
Androgenic Alopecia - Pipeline by SWITCH Biotech LLC, H2 2014
Androgenic Alopecia - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Androgenic Alopecia Therapeutics - Recent Pipeline Updates, H2 2014
Androgenic Alopecia - Dormant Projects, H2 2014
List of Figures
Number of Products under Development for Androgenic Alopecia, H2 2014
Number of Products under Development for Androgenic Alopecia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

[JayM]

Is there not one for 2015?

[sosa56]

Seems this is the latest one, but hardly much is likely to have changed in 8 months

[joachim]

wasn't aware that such a report exists.
i think it's a good idea to buy it. i would even say, we have to buy the 2015 version as well, if it gets released by the end of the year, then we can compare changes.
if nobody is interested to see the progress/changes, then it probably makes sense to wait for the 2015 version.

but i see a problem here: we're not allowed to buy it and then put it online for everyone, are we? we need to workaround this somehow.

[sosa56]

Sheeet if each of the people that have viewed this thread put in like $5 we'd be able to buy the report, obviously like when you buy a film or music track you're not allowed to distribute it, but one someone has paid for a piece of IP it's up to them what they do with it right? Someone could always buy the report and then pass it onto a friend and that friend could upload the report onto a file hoster like mega.nz and then post the link here from an anon account, it's not as if the report publisher would get $2000 out of readers on this forum any other way right?

[sosa56]

So noone up on this? This forum makes me laugh honestly, always see threads where guys are discussing buying grey market chems from China that haven't finished clinical trials to slap them on their heads lol but won't put in for a comprehensive report that could go a long way to answering all of our questions on the state of the market leading up to the conference in Nov. smh

[cratusg]

Okey so we need a trusted veteran on this forum which can make things happend. I am willing to pay 5 bucks!

It seems we have like 4-5 who are willing to pay. How many more can we get?

[NeedHairASAP]

Okey so we need a trusted veteran on this forum which can make things happend. I am willing to pay 5 bucks!

It seems we have like 4-5 who are willing to pay. How many more can we get?

only $1,975 to go!

Lets do this!!!!!

[sosa56]

I would nominate Desmond but he never seems to be around, how was the funding for sending Desmond to the conference in Korea last year organized? Did Desmond have a paypal that everyone just transferred into?